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About half of all patients with oesophageal squamous cell carcinoma
(OSCC) have locoregional disease at diagnosis; however, 40–50% of
them die of metastatic relapse within the first 2 years after tumour
resection (Roder et al, 1994). Thus, the prognosis of patients with
locally advanced OSCC remains poor despite significant progress in
surgical treatment. Several regimens of cisplatin-based chemo-
therapy and/or chemoradiotherapy have been applied to treatment of
patients with OSCC (Kok et al, 1996; Stahl et al, 1996; Bosset et al,
1997); however, these clinical trials have not shown significant
improvement in overall survival so far. These results mean that it
may be necessary to distinguish responders from non-responders in
cisplatin-based chemotherapy in order to determine a more effective
therapy and to improve the poor prognosis of this disease.
The nm23 gene was identified originally as an anti-metastatic
influence whose expression was correlated inversely with tumour
metastatic potential in murine melanoma cell lines (Steeg et al,
1988). Subsequently, several studies have demonstrated the
favourable clinical outcome of overexpression of nm23-H1 in
human malignant tumours (Florenes et al, 1992; Tokunaga et al,
1993; Iizuka et al, 1995), although conflicting data have been
reported (Higashiyama et al, 1992; Easty et al, 1996; Lindmark et al,
1996). More interestingly, nm23-H1 has been shown to relate to
sensitivity to cisplatin in several malignant tumours (Ferguson et al,
1996; Scambia et al, 1996; Freije et al, 1997). Our preliminary study
also showed that reduced expression of nm23-H1 protein was asso-
ciated with poor prognosis of patients with OSCC. However, we
observed that there was a lack of association between the expression
and prognosis of patients with OSCC who did not undergo cisplatin-
based chemotherapy (data not shown). Therefore, in the present
study, we focused on a role for nm23-H1 in responsiveness to
cisplatin-based chemotherapy in OSCC patients, and we examined
nm23-H1 expression in 32 primary tumours of OSCC patients who
underwent the same protocol of cisplatin-based chemotherapy
following tumour resection. Furthermore, we evaluated the direct
correlation between tumour nm23-H1 expression and resistance
and/or sensitivity to chemotherapeutic agents including cisplatin
using an antisense-transfection assay.
MATERIALS AND METHODS
Patients
Between April 1989 and July 1996, we had performed cisplatin-
based chemotherapy following resection in 35 OSCC patients with
stage II–IV defined by the TNM classification of the International
Union Against Cancer (1997). Of the 35 patients two died of
subarachnoid haemorrhage and myocardial infarction during
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Summary Recently, nm23-H1, an anti-metastasis gene, has been reported to correlate with sensitivity to chemotherapeutic agents including
cisplatin in human breast and ovarian carcinoma cells. The aim of this study was to evaluate a role for nm23-H1 in responsiveness to
cisplatin-based chemotherapy in patients with oesophageal squamous cell carcinoma (OSCC). The expression of nm23-H1 protein was
examined immunohistochemically in 32 eligible patients with OSCC who underwent adjuvant chemotherapy with cisplatin, etoposide, and 
5-fluorouracil after tumour resection. Fifteen (46.9%) of 32 patients were positive for nm23-H1 staining and 17 (53.1%) were negative. Both
disease-free survival and overall survival rates of nm23-H1-negative patients were significantly shorter than in nm23-H1-positive patients 
(P < 0.01 for both). There was no significant difference in clinicopathologic characteristics between nm23-H1-positive and nm23-H1-negative
groups. Multivariate analysis also showed that nm23-H1 expression was the most significant factor for overall survival of OSCC patients
included in this study (P = 0.0007). To further study the role of nm23-H1, a human OSCC cell line (YES-2) was transfected with a plasmid
containing a fragment of the nm23-H1 cDNA in an antisense orientation. Reduced expression of nm23-H1 protein in the antisense-
transfected (AS) clones was found by Western blot analysis as compared to wild-type YES-2 and YES-2/Neo (clone transfected with the
neomycin resistance gene alone). MTT (3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H tetrazolium bromide) assay showed that reduced
expression of the nm23-H1 protein in AS clones was consistent with the degree of increased resistance to cisplatin but not etoposide or 
5-fluorouracil. These data support the conclusion that reduced expression of nm23-H1 may be associated with resistance to cisplatin,
suggesting the value of nm23-H1 expression as a prognostic marker for OSCC patients who are to undergo cisplatin-based chemotherapy.
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Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japanfollow-up periods respectively. One patient was excluded because
of loss to follow-up. Therefore, the present study was undertaken
in 32 patients retrospectively selected. One course of cisplatin-
based chemotherapy consisted of etoposide 120 mg m–2 per day
and 5-fluorouracil (5-FU) 500 mg m–2 per day by intravenous (i.v.)
continuous infusion on days 3–5, and cisplatin 50 mg m–2 per day
by i.v. bolus infusion on days 1 and 8. Seven (21.9%) of 32
patients underwent only 1 course of this regimen because of side-
effects, while 25 patients (78.1%) underwent two course of this
regimen following resection. All patients were subjected to
computerized tomography and magnetic resonance imaging every
3 months. These imaging techniques revealed metastatic relapse in
24 (75%) of the 32 patients, and 23 of the 24 patients died of
metastatic relapse within the median follow-up period of 65
months (range 21–105 months).
Immunohistochemical analysis for NM23-H1 protein
The expression of nm23-H1 protein was examined immunohisto-
chemically in 32 primary tumours of 32 eligible patients. Following
resection, tumour samples were fixed in 10% formaldehyde solution
and embedded in paraffin. Four-micrometre-thick sections were
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Figure 1 Immunohistochemical staining for nm23-H1 protein in oesophageal squamous cell carcinoma. (A) Representative nm23-H1-positive case which
demonstrates intense nm23-H1 immunoreactivity in the cytoplasm of tumour cells (original magnification ´ 100). (B) Representative nm23-H1-negative case in
which expression in tumour cells was similar to that of nontumourous tissue (original magnification ´ 200)
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Figure 2 Overall survival (A) and disease-free survival (B) curves of
patients with OSCC according to nm23-H1 status
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Figure 3 Down-regulation of both intrinsic mRNA and protein level of
nm23-H1 by antisense nm23-H1 cDNA transfection. (A) Intrinsic nm23-H1
mRNA expression detected by RT-PCR with primers which yield a 685-bp
product and can exclude exogenously transfected antisense nm23-H1 cDNA.
(B) Expression of b-actin gene (internal control) amplified simultaneously by
RT-PCR. (C) Expression of nm23-H1 protein by Western blot analysis with
mAb H1-229. Lanes 1–5 are YES-2, YES-2/Neo, YES-2/AS-5, YES-2/AS-12
and YES-2/AS-29 respectively. Relative expression of nm23-H1 protein in
YES-2/Neo, YES-2/AS-5, YES-2/AS-12 and YES-2/AS-29 was 0.92, 0.56,
0.04 and 0.41 respectively, when compared to that of YES-2. Lane M is a
molecular weight marker, 1 kB DNA ladder (Gibco-BRL, Rockville, MD, USA)deparaffinized in xylene and progressively rehydrated in decreasing
concentrations of alcohol. Immunohistochemical staining was
performed by the avidin–biotin affinity method with the use of
OmniTags (Lipshaw, Pittsburgh, PA, USA). Briefly, the sections
were immersed in protein blocking agent for 5 min to reduce non-
specific staining and incubated at room temperature for 120 min
with 1 mg ml–1 anti-human nm23-H1 monoclonal antibody (H1-229,
Seikagaku, Tokyo, Japan) (Tokunaga et al, 1993; Iizuka et al, 1995).
These sections were washed in chilled PBS three times and were
reacted with biotinylated polyvalent antibody at room temperature
for 30 min. After being washed in PBS, the sections were reacted
with streptavidin–alkaline phosphatase reagent at room temperature
for 30 min. Finally, the sections were treated with fast red
chromogen for 10 min. Normal mouse IgG was used as a negative
control instead of the primary antibodies. The sections were
counterstained lightly with haematoxylin. We judged that nm23-H1
protein was positive when more than 20% of the cancer cells were
more strongly stained than stromal cells (Figure 1).
Antisense vector for nm23-H1 cDNA
Nm23-H1 cDNA was isolated by reverse transcription polymerase
chain reaction (RT-PCR) using total RNA purified from human
peripheral blood mononuclear cells. The primers for nm23-H1 were
as follows: sense primer, 5¢-GCGTCTAGAGGAACCATGGC-
CAACTGTGAGCGT-3¢ and antisense primer, 5¢-GTCGCGGCC-
GCTCTGCCCTCCTGTCATTCATAGAT-3¢. The PCR fragment
was cloned into a NotI/XbaI site of the pcDNA II plasmid
(Invitrogen, San Diego, CA, USA), and the nucleotide sequence was
confirmed by automatic DNA sequencer DSO-1000 (Shimazu,
Kyoto, Japan). The same fragment then was recloned into a
NotI/XbaI site of the pRc/CMV eukaryotic expression vector
(Invitrogen, San Diego, CA, USA).
Tumour cells and transfection
YES-2 cells, a human OSCC cell line (Oka et al, 1996; Yamamoto
et al, 1997), were maintained in Dulbecco’s modified Eagle’s
medium (Nissui, Tokyo, Japan) supplemented with 5% heat-
inactivated fetal serum, 100 U ml–1 penicillin G, and 100 mg ml–1
streptomycin. Subconfluent cultures in 100 mm Petri dishes were
transfected with 5 mg of antisense nm23-H1 expression plasmid or
vector alone using the lipofectAMINE reagent (Life Technologies,
Rockville, MD, USA) according to the manufacturer’s instructions.
G418 (600 mg ml–1) (Life Technologies, Rockville, MD, USA) was
added to the cells 48 h later. G418-resistant clones were isolated
and expanded in culture medium containing 200 mg ml–1 of G418.
Effects of antisense transfection on intrinsic nm23-H1
mRNA
The RT-PCR method was performed as previously described (Iizuka
et al, 1995). Briefly, cDNA was synthesized from 0.5 mg of total
RNA using random hexadeoxynucleotide primers (Takara, Otsu,
Japan) and was amplified using AmpliTaq DNA polymerase (Perkin-
Elmer/Cetus, San Diego, CA, USA). The primers used to detect only
intrinsic nm23-H1 mRNA were 5¢-GCAGCCGGAGTTCAAACC-
TAA-3¢ (sense) and 5¢-GCTGGGAGGAAGCATTTTAATCA-3¢
(antisense), which yielded a 685-bp product and can exclude exoge-
nously transfected antisense nm23-H1 cDNA. The primers for the b-
actin gene were 5¢-ATGGATGATGATATCGCCGCGCT-3¢ (sense)
and 5¢-CGGACTCGTCATACTCCTGCTTG-3¢ (antisense), which
yielded a 1224-bp product. PCR reaction was performed for 27
cycles according to the following parameters: denaturation at 94°C
for 1 min, annealing at 55°C for 45 s, extension at 72°C for 2 min.
The PCR products were separated electrophoretically on a 1%
agarose gel and stained with ethidium bromide.
Western blot analysis
Western blot analysis was also performed according to previously
described method (Iizuka et al, 1995). Briefly, protein samples (50
mg) were subjected to 12.5% sodium dodecyl sulphate polyacry-
lamide gel electrophoresis (SDS-PAGE) followed by transfer onto
nitrocellulose filters. The antibody used was monoclonal antibody
(H1-229) which is specifically directed against NM23-H1 protein
(Tokunaga et al, 1993). For detection of the immunocomplex, the
enhanced chemiluminescence (ECL) Western blotting detection
system (Amersham, Tokyo, Japan) was used. Finally, the
membrane was exposed to XAR-5 film (Eastman-Kodak,
Rochester, NY, USA) for 30 s at room temperature.
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Table 1 nm23-H1 expression and clinicopathologic characteristics
Factors nm23-H1(+) nm23-H1(–) P-value
Years NS
<60 7 11
³60 8 6
Sex NS
Male 13 15
Female 2 2
Location NS
Upper thoracic 1 3
Mid-thoracic 11 8
Lower thoracic 3 6
pT NS
pT1 0 2
pT2 3 3
pT3 7 7
pT4 5 5
pN NS
pN0 2 1
pN1 13 16
pM NS
pM0 12 12
pM1 3 5
pTNM stage NS
II 4 5
III 8 7
IV 3 5
Differentiation NS
Well 2 2
Moderate 9 10
Poor 4 5
Venous invasion NS
(+) 9 9
(–) 6 8
Lymphatic invasion NS
(+) 14 13
(–) 1 4
Resectability NS
R0 6 5
R1 4 7
R2 5 5
EFP therapy NS
1 course 3 4
2 course 12 13
NS, not significant; EFP, etoposide, 5-fluorouracil and cisplatin.Analysis of integration of antisense nm23-H1 cDNA
We used a PCR method to confirm the integration of antisense
nm23-H1 cDNA into YES-2 cells by previously reported methods
(de Geovani et al, 1996). PCR was performed on genomic DNA
extracted by DNAzol (Life Technologies, Rockvile, MD, USA),
and 0.5 mg was used for each PCR reaction in 100 ml final volume.
The following primers were used to detect antisense nm23-H1
cDNA fragment of the pRc/CMV eukaryotic expression vector:
sense primer, 5¢-GAGATTATCAAGCGTTTTGAGCA-3¢ (posi-
tion 151–173, exon 2) and antisense primer, 5¢-GTATAATGTTC-
CTGCCAACTTGT-3¢ (position 436–414, exon 4–5), which
yielded a 286-bp product. PCR reaction was performed for 30
cycles according to the following parameters: denaturation at 94°C
for 30 s, annealing at 55°C for 45 s, extension at 72°C for 90 s.
Assessment for in vitro cytotoxity induced by
chemotherapeutic agents
Cisplatin and etoposide were purchased from Nippon Kayaku
(Tokyo, Japan), whereas 5-FU was obtained from Kyowa Hakko
(Tokyo, Japan). MTT (3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-
2H tetrazolium bromide; Dojindo, Tokyo, Japan) assay was
performed to evaluate the in vitro cytotoxity induced by cisplatin,
etoposide and 5-FU in YES-2, YES-2/Neo, and AS clones. The
cells were plated at 5 ´ 103 per 100 ml in 96-well plates in
Dulbecco’s modified Eagle’s medium with 5% fetal calf serum,
and allowed to attach overnight. Three wells were treated with
each drug concentration of 0.01 mg ml–1 to 20 mg ml–1 of cisplatin
or etoposide or 0.01 mg ml–1 to 50 mg ml–1 of 5-FU. After 48 h, cell
viability was calculated as the percentage of control cultures
which were not exposed to drugs. Thus, the experiments were
performed in triplicate and the results were evaluated using the
means of three experiments.
Statistical analysis
The c2 test with Yates’ correction or Fisher’s exact test was used 
to elucidate the correlation between nm23-H1 expression and
clinicopathological characteristics. All survival and disease-free
survival data were analysed by the Kaplan–Meier method using
Cox–Mantel comparisons for statistical significance (Kaplan and
Meier, 1958; Cox, 1972). Multivariate analysis by the Cox propor-
tional hazards regression model was performed to evaluate the
factors responsible for overall survival of OSCC patients who
underwent cisplatin-based chemotherapy after tumour resection.
Pearson’s correlation test was used to analyse the relationship
between nm23-H1 protein level and ID50 of cisplatin in YES-2 and
the antisense transfectants.
RESULTS
Immunohistochemical study
Of 32 patients included in this study, 15 (46.9%) were positive for
nm23-H1 staining and 17 (53.1%) were negative. In 15 (88.2%) of
17 nm23-H1-negative cases, the intensity of nm23-H1 immuno-
staining of the primary tumour was weaker than corresponding
normal oesophageal epithelium (data not shown). The disease-free
survival and overall survival curves for patients with positive or
negative nm23-H1 staining are shown in Figure 2. Overall 1-, 
3- and 5-year survival rates of nm23-H1-negative patients were
41.2%, 17.6% and 8.8% respectively. By contrast, those of nm23-
H1-positive patients were 93.3%, 63.8% and 54.7% respectively.
Disease-free 1-, 3- and 5-year survival rates of nm23-H1-negative
patients were 29.4%, 8.8% and 8.8% respectively, while those of
nm23-H1-positive patients were 86.7%, 59.3% and 42.3% respec-
tively. Thus, nm23-H1-negative patients had both significantly
shorter disease-free survival and overall survival than did nm23-
H1-positive patients (Figure 2, P < 0.01 for both). Multivariate
analysis also showed that, of ten factors examined, nm23-H1
expression was the most significant factor for overall survival of
OSCC patients who underwent cisplatin-based chemotherapy after
tumour resection (P = 0.0007, Table 1). Of the ten OSCC patients
who had poor resectability (R2 resection), two (40%) of five
patients with positive nm23-H1 staining are alive in condition of
relapse-free after this chemotherapy, on the contrary, all of the five
patients with negative nm23-H1 staining died of metastatic
relapse. As shown in Table 2, there was no significant difference in
the other clinicopathological characteristics between nm23-
H1-positive and nm23-H1-negative groups. No association was
observed between nm23-H1 expression and local immune
response such as lymphocyte infiltration (data not shown).
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Figure 4 PCR analysis of genomic DNA extracted from AS transfectants,
YES-2/Neo, and YES-2 parental cells for the presence of a plasmid
expressing antisense nm23-H1 cDNA fragment. Lanes 1–5 are YES-2, YES-
2/Neo, YES-2/AS-5, YES-2/AS-12 and YES-2/AS-29 respectively. Lane M is
a molecular weight marker, 1 kB DNA ladder (Gibco-BRL, Rockville, MD,
USA)
Table 2 Factors linked to overall survival
Factors Regression Standard t-value P-value
coefficient error
Nm23-H1 staining 2.1023 0.5549 3.789 0.0007
Sex 1.9963 0.6733 2.920 0.0068
Tumour location 0.3590 0.3091 1.162 0.2552
Table 3 In vitro inhibitory effect of cisplatin on control- and antisense
nm23-H1 transfected tumour cell lines
Cell line nm23-H1 protein level ID50 (mg ml–1)
YES-2 1.00 1.3
YES-2/Neo 0.92 1.1
YES-2/AS-5 0.56 2.1
YES-2/AS-12 0.04 4.1
YES-2/AS-29 0.41 2.0
ID50, the cisplatin dose at which the cell number is 50% of control (untreated)
cultures as determined by MTT assay.In vitro cytotoxic effect of chemotherapeutic agents on
control- and antisense nm23-H1-transfected cells
Transfection of antisense nm23-H1 cDNA was performed to eval-
uate the relation of nm23-H1 to cytotoxity induced by chemothera-
peutic agents in OSCC cells. Of 30 G418-resistant clones isolated
in culture medium containing 600 mg ml–1 of G418, our RT-PCR
method selected these clones, YES-2/AS-5, YES-2/AS-12 and
YES-2/AS-29, which showed reduced expression of intrinsic
nm23-H1 mRNA (Figure 3). Subsequently, the nm23-H1 protein
level in these clones was analysed by Western blot analysis (Figure
3). Relative expression of nm23-H1 protein in YES-2/AS-5, YES-
2/AS-12, YES-2/AS-29 and YES-2/Neo calculated by densito-
meter was 0.56, 0.04, 0.41 and 0.92 respectively, when compared to
that of YES-2 cells (parental cell). Furthermore, the integration of
antisense nm23-H1 cDNA into YES-2/AS-5, YES-2/AS-12 and
YES-2/AS-29 was confirmed by PCR analysis with genomic DNA
extracted from these cells (Figure 4). Namely, a spliced 286-bp
product was amplified from genomic DNA of the AS clones as well
as from a plasmid DNA, but not from YES-2 and YES-2/Neo cells.
We used MTT assay in order to evaluate in vitro cytotoxicity
induced by cisplatin, etoposide and 5-FU. There was no difference in
growth rates between the AS clones and YES-2 or YES-2/Neo (data
not shown). Increased resistance of the AS clones to cisplatin was
observed when compared to YES-2 or YES-2/Neo (Figure 5). The
ID50 of YES-2/AS-5, YES-2/AS-12, YES-2/AS-29 and YES-2/Neo
for cisplatin treatment was 2.1, 4.1, 2.0 and 1.1 mg ml–1 respectively.
A reduction of twofold in the expression level of nm23-H1 by YES-
2/AS-5 and YES-2/AS-29 resulted in twofold increased resistance
to cisplatin as compared to YES-2/Neo. Furthermore, a reduction 
of 23-fold in the expression level of nm23-H1 by YES-2/AS-12
resulted in fourfold increased resistance to cisplatin as compared to
YES-2/Neo (Table 3). Thus, nm23-H1 protein level in the five cells
including the parental cell was associated inversely with ID50 of
CDDP (r= –0.935, P< 0.02). By contrast, there was no difference in
resistance to etoposide or 5-FU between AS clones and YES-2/Neo,
although YES-2/AS-12, with markedly reduced expression of
nm23-H1 protein, showed increased resistance to 5-FU (Figure 5).
DISCUSSION
Cisplatin is one of the key drugs for treatment of patients with
OSCC (Kok et al, 1996). However, cisplatin-based chemotherapy
dose not sufficiently improve their overall survival, even when
combined with additional irradiation (Stahl et al, 1996; Bosset et
al, 1997). The results of these clinical trials suggest that it might be
necessary to select the most effective therapy for each case in order
to improve survival of patients with OSCC, especially advanced
OSCC. Recent studies have elucidated several molecules, such 
as p53, GST-p and metalothionein, responsible for sensitivity 
to cisplatin (Timmer-Bosscha et al, 1993; Rusch et al, 1995;
Hishikawa et al, 1997). More recently, nm23-H1 has been reported
to correlate directly with sensitivity to cisplatin as well as other
alkylating agents by transfection assay (Ferguson et al, 1996) and
the expression of nm23-H1 protein has been shown to correlate
inversely with prognosis of patients with ovarian carcinoma after
cisplatin-based chemotherapy (Scambia et al, 1996).
With regard to OSCC, work by Patel et al (1997) has shown that
reduced expression of nm23 protein was a factor associated with
poor prognosis of OSCC patients after resection; however, they
did not refer to the relation of nm23 expression to drug sensitivity.
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Figure 5 Dose–response of parental YES-2 (n n), YES-2/Neo (n), and AS
transfectants (YES-2/AS-5, YES-2/AS-12 and YES-2/AS-29, l l, s and l
respectively) to cisplatin (A), 5-fluorouracil (B) and etoposide (C). Cells
(5 ´ 103) were plated with semilog doses of cisplatin or etoposide ranging
from 10 ng ml–1 to 20 mg ml–1 and 5-fluorouracil ranging from 10 ng ml–1 to 
50 mg ml–1. On day 2 of culture, the number of viable cells per well was
determined by MTT assay. The experiments were performed in triplicate and
the mean value was plottedOur immunohistochemical study showed that expression of nm23-
H1 protein was correlated inversely with disease-free survival and
overall survival rates of OSCC patients who underwent cisplatin-
based chemotherapy following resection. Multivariate analysis
showed that nm23-H1 status was most responsible for overall
survival of OSCC patients after cisplatin-based chemotherapy.
Furthermore, we confirmed that, of the ten OSCC patients who
had poor resectability (R2 resection), two (40%) of five patients
with positive nm23-H1 staining were alive and relapse free after
this chemotherapy, on the contrary, all of the five patients with
negative nm23-H1 staining died of metastatic relapse. Thus,
nm23-H1 is likely to relate to responsiveness to cisplatin-based
chemotherapy in patients with OSCC. Stahl et al (1996) have
reported that overall 3-year survival rate was 33% in patients 
with T2–4 oesophageal carcinoma who underwent preoperative
chemoradiotherapy and surgery. Likewise, we found that overall 
3-year survival rate of 32 OSCC patients included in this study
was 39.6%. However, that of 15 OSCC patients with positive
nm23-H1 staining was 63.8% after this chemotherapy. These
results suggest that nm23-H1 status may be a useful marker for
cisplatin-based chemotherapy in patients with OSCC.
MTT assay showed enhanced resistance to cisplatin, but not
etoposide or 5-FU, in parallel to the degree of reduction of nm23-
H1 protein level in the OSCC cells examined. This result was most
consistent with the data reported by Freije et al (1997), except for
5-FU. The role of nm23-H1 in cisplatin-induced cytotoxicity
remains to be clarified. Ferguson et al (1996) have demonstrated
increased formation of interstrand DNA cross-links in the nm23-
H1 transfectants showing overexpression of nm23-H1, and there
was no difference in the rates of DNA repair. Since it also was
confirmed that the nm23-H1 level was increased in S phase (Caligo
et al, 1995), and cisplatin has the strongest cytotoxic effect in S-G2
phase (Nguyen et al, 1993), one possibility is that nm23-H1 may
play a role in cisplatin-induced cytotoxity via modulating the cell
cycle. However, our data with flow cytometry demonstrated that
there was no difference in the cell cycle between parental YES-2
and YES-2/Neo and YES-2/AS-12 (data not shown). Recent
studies have shown that mitochondria play an important role in the
cytotoxicity or apoptosis induced by cisplatin, but not 5-FU or
etoposide (Andrews and Albright, 1992; Olivero et al, 1995). The
MTT assay is considered to be a representative mitochondrial func-
tion assay (Berridge and Tan, 1993); therefore, it is possible that
nm23-H1 may be directly related to mitochondrial dysfunction
induced by cisplatin in OSCC. This concept is supported by a
previous report that respiration could be aided by ADP formed by
adenylate kinase or nm23/NDP kinase in mitochondria (Gauthier et
al, 1990). Further studies are required to clarify the roles of nm23-
H1/NDP kinase A in mitochondrial dysfunction and/or apoptosis
induced by cisplatin in human OSCC cells.
There were no differences in resistance to 5-FU between YES-
2/AS-5 and YES-2/AS-29 and YES-2/Neo; however, YES-2/AS-
12, with markedly reduced expression of nm23-H1 protein,
showed increased resistance to 5-FU. The reason why only YES-
2/AS-12 showed increased resistance to 5-FU remain unknown. It
has been reported that several molecules such as Bcl-2 family
proteins and dihydropyrimidine dehydrogenase contributed to the
sensitivity to 5-FU (McLeod et al, 1998; Nita et al, 1998). Current
study is attempting to clarify the relation or the interaction
between nm23-H1 and these molecules in YES-2/AS-12.
In conclusion, the close relation of nm23-H1 status with resis-
tance to cisplatin suggests that it may be a useful marker for
cisplatin-based chemotherapy in patients with OSCC. More inter-
estingly, gamma linoleic acid, n-6 polyunsaturated fatty acid, was
reported to increase the expression of nm23-H1 in human cancer
cells (Jiang et al, 1998). Thus, modulating tumour nm23-H1
expression may be considered as a potential therapeutic strategy in
combination with cisplatin treatment in OSCC patients.
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